DeepMed Research

ABBVIE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: ABT-263
Drug: FCR
Drug: BR

First Posted Date: 2009-03-25

Last Posted Date: 2013-06-07

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 32

Registration Number: NCT00868413

Locations: 🇺🇸
Site Reference ID/Investigator# 21622, Baltimore, Maryland, United States
🇺🇸
Site Reference ID/Investigator# 17841, La Jolla, California, United States
🇺🇸
Site Reference ID/Investigator# 25899, Stanford, California, United States

and more 3 locations

A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Biological: adalimumab
Drug: placebo

First Posted Date: 2009-03-02

Last Posted Date: 2014-09-05

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 274

Registration Number: NCT00853099

Locations: 🇯🇵
Site Reference ID/Investigator# 47228, Okinawa, Japan
🇯🇵
Site Reference ID/Investigator# 47183, Chikushino, Japan
🇯🇵
Site Reference ID/Investigator# 47159, Chiba, Japan

and more 62 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Phase 2

Completed

Conditions: Chronic Hepatitis C Virus Infection

Interventions: Other: Placebo for ABT-333
Drug: ABT-333
Drug: Pegylated interferon
Drug: Ribavirin

First Posted Date: 2009-02-26

Last Posted Date: 2018-07-02

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 30

Registration Number: NCT00851890

Locations: 🇺🇸
Site Reference ID/Investigator# 16106, Chapel Hill, North Carolina, United States
🇺🇸
Site Reference ID/Investigator# 16103, Anaheim, California, United States
🇺🇸
Site Reference ID/Investigator# 16124, Los Angeles, California, United States

and more 5 locations

Safety, Tolerability and PK Study of Single Doses of ABT-450 With and Without Ritonavir to Treat Hepatitis C Virus (HCV) Genotype 1

Phase 1

Completed

Conditions: HCV Infection

Interventions: Drug: placebo for ABT-450
Drug: ABT-450
Drug: Placebo for ritonavir
Drug: ritonavir

First Posted Date: 2009-02-24

Last Posted Date: 2017-11-20

Lead Sponsor: AbbVie

Target Recruit Count: 87

Registration Number: NCT00850044

Locations: 🇺🇸
Site Reference ID/Investigator# 15981, Waukegan, Illinois, United States

A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission

Phase 4

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Biological: adalimumab
Drug: methotrexate

First Posted Date: 2008-12-16

Last Posted Date: 2013-12-16

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 33

Registration Number: NCT00808509

Locations: 🇸🇪
Site Reference ID/Investigator# 14022, Lund, Sweden
🇸🇪
Site Reference ID/Investigator# 20241, Skoevde, Sweden
🇸🇪
Site Reference ID/Investigator# 14023, Malmo, Sweden

and more 5 locations

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

Phase 2

Completed

Conditions: Metastatic Melanoma
Skin Cancer
Melanoma

Interventions: Drug: temozolomide
Other: Placebo
Drug: ABT-888

First Posted Date: 2008-12-09

Last Posted Date: 2018-06-06

Lead Sponsor: AbbVie (prior sponsor, Abbott)

Target Recruit Count: 346

Registration Number: NCT00804908

Chronic Plaque Psoriasis (Ps) Registry

Completed

Conditions: Chronic Plaque Psoriasis

First Posted Date: 2008-12-01

Last Posted Date: 2024-03-15

Lead Sponsor: AbbVie

Target Recruit Count: 6065

Registration Number: NCT00799877

Locations: 🇺🇸
MidSouth Dermatology /ID# 17128, Bartlett, Tennessee, United States
🇺🇸
Northwestern University Feinberg School of Medicine /ID# 28169, Chicago, Illinois, United States
🇺🇸
Brigham Dermatology Associates /ID# 28207, Boston, Massachusetts, United States

and more 336 locations

Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis

Phase 2

Completed

Conditions: Endometriosis

Interventions: Drug: Leuprorelin Acetate Depot
Drug: Elagolix
Drug: Placebo to Leuprorelin Acetate
Drug: Placebo to Elagolix

First Posted Date: 2008-11-25

Last Posted Date: 2018-09-10

Lead Sponsor: AbbVie

Target Recruit Count: 174

Registration Number: NCT00797225

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Phase 1

Completed

Conditions: CD20-Positive Lymphoid Malignancies
Non-Hodgkin's Lymphoma
Chronic Lymphoid Leukemia
Hematological Malignancies

Interventions: Drug: rituximab
Drug: ABT-263

First Posted Date: 2008-11-11

Last Posted Date: 2025-02-20

Lead Sponsor: AbbVie

Target Recruit Count: 29

Registration Number: NCT00788684

Locations: 🇺🇸
Univ of Wisconsin Hosp/Clinics /ID# 21701, Madison, Wisconsin, United States
🇦🇺
Peter MacCallum Cancer Ctr /ID# 25067, Melbourne, Victoria, Australia
🇺🇸
Stanford University School of Med /ID# 9782, Stanford, California, United States

and more 3 locations

Juvenile Idiopathic Arthritis (JIA) Registry

Completed

Conditions: Juvenile Idiopathic Arthritis
JIA

Interventions: Biological: adalimumab
Drug: Methotrexate

First Posted Date: 2008-10-31

Last Posted Date: 2025-02-04

Lead Sponsor: AbbVie

Target Recruit Count: 849

Registration Number: NCT00783510

Locations: 🇺🇸
University of Louisville /ID# 23507, Louisville, Kentucky, United States
🇺🇸
Arthritis Care Spec. of MD /ID# 21961, Ellicott City, Maryland, United States
🇺🇸
North Shore University Hospital /ID# 21022, New Hyde Park, New York, United States

and more 89 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy